{
    "output": [
        [
            "Xenon Pharmaceuticals Inc",
            "COMP",
            "Outline",
            "Key Milestones for 2018",
            "CONCEPT"
        ],
        [
            "Xenon Pharmaceuticals Inc",
            "COMP",
            "Expect",
            "Ongoing XEN1101 Phase 1 Clinical Trial Completed by Mid-Year",
            "EVENT"
        ],
        [
            "Xenon Pharmaceuticals Inc",
            "COMP",
            "Anticipate",
            "Completed XEN901 Phase 1 Clinical Trial by Second Half of this Year",
            "EVENT"
        ],
        [
            "Xenon Pharmaceuticals Inc",
            "COMP",
            "Anticipate",
            "Both XEN1101 and XEN901 in Phase 2 Development by End of this Year",
            "CONCEPT"
        ],
        [
            "Xenon Pharmaceuticals Inc",
            "COMP",
            "Had",
            "Cash and Cash Equivalents and Marketable Securities $43.7 Million as of Dec 31, 2017",
            "ECON_INDICATOR"
        ],
        [
            "Xenon Pharmaceuticals Inc",
            "COMP",
            "Anticipate",
            "Sufficient Cash to Fund Operations into Mid-2019",
            "ECON_INDICATOR"
        ]
    ]
}